Healthcare
FDA gathers stakeholder views on regulating generative AI in medtech
Patients, clinicians, and medtech companies submitted hundreds of comments as the FDA develops guidance for generative AI in medical devices.
The US Food and Drug Administration received hundreds of comments from patients, physician groups, and medical-device companies on how generative AI should be regulated in medtech. The feedback comes as the agency prepares guidance for generative AI used in medical devices. Stakeholders are contributing views on oversight, safety, accountability, and the practical challenges of evaluating systems that may change their outputs over time. The consultation reflects the growing presence of generative AI in clinical and medical-device workflows. Clear rules could help manufacturers understand evidence requirements and help providers assess whether tools are safe for patient care. The process also shows that regulation is being shaped by a broad group of participants rather than technology companies alone. Its eventual outcome may affect product development, validation, monitoring, and deployment across US healthcare settings.
Original source: Healthcare Dive